XTX Topco Ltd Buys Shares of 30,949 Exelixis, Inc. (NASDAQ:EXEL)

XTX Topco Ltd purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL) during the 4th quarter, Holdings Channel reports. The firm purchased 30,949 shares of the biotechnology company’s stock, valued at approximately $1,031,000.

A number of other hedge funds also recently made changes to their positions in EXEL. Invesco Ltd. boosted its position in Exelixis by 308.1% during the 4th quarter. Invesco Ltd. now owns 3,975,241 shares of the biotechnology company’s stock worth $132,376,000 after acquiring an additional 3,001,204 shares during the period. Norges Bank bought a new stake in shares of Exelixis during the fourth quarter valued at about $94,867,000. Arrowstreet Capital Limited Partnership lifted its holdings in Exelixis by 104.4% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,159,395 shares of the biotechnology company’s stock worth $105,208,000 after purchasing an additional 1,613,482 shares during the period. Allspring Global Investments Holdings LLC grew its position in Exelixis by 82.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company’s stock valued at $52,884,000 after buying an additional 704,786 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in Exelixis by 1,637.9% during the 4th quarter. Wells Fargo & Company MN now owns 746,286 shares of the biotechnology company’s stock valued at $24,851,000 after buying an additional 703,343 shares during the period. Institutional investors own 85.27% of the company’s stock.

Insider Activity

In related news, EVP Patrick J. Haley sold 52,636 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the sale, the executive vice president now directly owns 303,310 shares in the company, valued at approximately $11,216,403.80. This trade represents a 14.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Mary C. Beckerle sold 12,210 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the transaction, the director now owns 30,406 shares in the company, valued at approximately $1,060,561.28. This represents a 28.65 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 140,343 shares of company stock worth $5,177,234. 2.85% of the stock is owned by corporate insiders.

Exelixis Price Performance

Exelixis stock opened at $36.54 on Wednesday. Exelixis, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $40.02. The firm’s 50 day simple moving average is $36.26 and its 200-day simple moving average is $34.09. The company has a market cap of $10.23 billion, a P/E ratio of 20.64, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, analysts expect that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently issued reports on EXEL shares. JMP Securities reiterated a “market outperform” rating and issued a $41.00 price objective on shares of Exelixis in a report on Thursday, January 23rd. Oppenheimer lowered Exelixis from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $41.00 to $33.00 in a research note on Friday, January 24th. StockNews.com raised Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 19th. Citigroup raised their target price on Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Finally, Stephens reiterated an “equal weight” rating and issued a $29.00 price target on shares of Exelixis in a research report on Wednesday, February 12th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.59.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.